Steve Loutskou

Steve Loutskou is a declared insider of Restart Life Sciences Corp., with filings sourced from SEDI. We count 14 filings; the first trade dates from 20 June 2025 and the latest from 6 August 2026.

Both buying and selling appear: 5 purchases worth €4,597, against 1 sale worth €123k. Netting one side against the other leaves €118k of net selling. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 2 option exercises. So far in 2026, the count stands at 5 purchases and no sales.

A typical purchase (the median) is worth €975. The 5 purchases reviewed show no overlap with other insiders buying the same stock within a month.

The newest entry dates from 7 August 2026: an open-market purchase of €975, in Restart Life Sciences Corp. Filings reach the SEDI feed a median of 1 day after the trade. Until a filing is published, the market cannot know about the trade. Every figure here comes from the filings published by SEDI and describes the past, not future prices; it is not investment advice.